Evommune (EVMN) Net Cash Flow (2024 - 2026)

Evommune (EVMN) has 3 years of Net Cash Flow data on file, last reported at $4.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $4.2 million, up 140.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (changed N/A YoY), and the FY2025 annual result was $29.0 million, up 327.23% from the prior year.
• Net Cash Flow slipped to $4.2 million in Q1 2026 per EVMN's latest filing, from $17.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $17.2 million in Q4 2025 and troughed at -$10.6 million in Q1 2025.
• A 3-year average of $2.3 million and a median of $1.2 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow surged 1012.11% in 2025, then surged 140.27% in 2026.
• A 3-year view of Net Cash Flow shows it stood at -$1.9 million in 2024, then surged by 1012.11% to $17.2 million in 2025, then sank by 75.37% to $4.2 million in 2026.
• Business Quant data shows EVMN's Net Cash Flow at $4.2 million in Q1 2026, $17.2 million in Q4 2025, and -$10.6 million in Q1 2025.